| abstract |
The invention relates to the use of cilansetron for treating non-obstipated male IBS patients and also for treating patients of both sexes, who suffer from irritable bowel syndrome (IBS), by administering the pharmaceutical preparation three times a day. In said preparation, alosetron, azasetron, dolasetron, granisetron, indisetron, itasetron, lerisetron, ondansetron, ramosetron, tropisetron, and/or (R)-zacopride are used as 5HT3 receptor antagonists. |